Perpetual Medicines
Perpetual Medicines is a 2023-founded, US-incorporated computational peptide therapeutics company (Shanghai and Boston) that uses AI, physics-based modeling, and synthetic chemistry to discover peptide drugs for oncology, autoimmune, and metabolic diseases.
- Company typePrivate
- Founded2023
- HeadquartersShanghai, China
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Perpetual Medicines does
Perpetual Medicines is a fully integrated computational peptide therapeutics company founded in 2023 and domiciled in the United States (Perpetual Medicines Corporation) with operational hubs in Shanghai, China and Boston, Massachusetts. The company is building a next-generation peptide drug discovery engine that combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access unexplored peptide chemical space. Its core product is a single platform that uses AI, deep learning, and physics-based computation to design peptide therapeutics with binding characteristics intended to rival or exceed monoclonal antibodies while being approximately 30 times smaller, enabling superior tissue penetration and intracellular target engagement. The platform also supports constrained structures and unnatural amino acids to produce novel biochemical properties.
The company operates in three therapeutic verticals — oncology (with a specific focus on β-catenin / WNT pathway targets), autoimmune diseases, and metabolic disorders — leveraging peptide modalities to address protein-protein interactions and other targets previously considered undruggable by small molecules or biologics. As a pre-clinical / early clinical stage company, Perpetual Medicines has no commercialized products and no disclosed revenue; its business model is internal pipeline advancement with the stated goal of moving its most advanced program to clinical stages. Its customers are effectively its own R&D programs, with the long-term monetization pathway implying out-licensing, co-development partnerships, or M&A.
Perpetual Medicines is led by a veteran management team: Co-founder, Chairman and CEO Kerry L. Blanchard (PhD, MD), previously CSO at Innovent and a senior R&D leader at Eli Lilly for ~18 years; CSO Xiang Ye (PhD), a 22-year Lilly veteran who led the discovery and development of Verzenio (abemaciclib); and CTO Ved Srivastava (PhD), former Head of Peptide Chemistry at GSK and Amylin who was instrumental in the development of Byetta, Symlin, and Bydureon. The company raised an $8 million seed round in December 2023 led by Chengwei Capital and in 2025 completed a merger with TandemAI, which concurrently closed a $22 million Series A extension, materially expanding its discovery and development footprint into both peptide and small molecule modalities.
Perpetual Medicines firmographics
Firmographics- Name
- Perpetual Medicines
- Legal name
- Perpetual Medicines Corporation
- Website
- https://perpetualmeds.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Perpetual Medicines is a 2023-founded, US-incorporated computational peptide therapeutics company (Shanghai and Boston) that uses AI, physics-based modeling, and synthetic chemistry to discover peptide drugs for oncology, autoimmune, and metabolic diseases.
- Ownership category
- akta.pro rank
Perpetual Medicines industry classification
Industry- Product category
- Computational Peptide Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro industry
- Therapeutic Peptides & Protein/Peptide BiologicsHealthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where Perpetual Medicines is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
Perpetual Medicines business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Distribution channels1 record
Marketing channels3 records
Perpetual Medicines product offering
Product offeringCore offering
Perpetual Medicines is a fully integrated computational peptide therapeutics company developing a next-generation peptide drug discovery engine. The platform combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space and design peptide therapeutics targeting previously undruggable proteins, with an internal pipeline focused on oncology, autoimmune, and metabolic diseases.
Product overview
Perpetual Medicines operates as a fully integrated computational peptide therapeutics company offering a single unified platform that combines computational physics methods and next-generation AI technologies with advanced synthetic chemistry. The platform is designed to access unexplored peptide chemical space, address previously undruggable targets, and accelerate peptide therapeutics development. The company focuses on oncology, autoimmune, and metabolic diseases, with operations in Shanghai, China and Boston, MA.
Differentiator
Problem solved
Functional benefit
Products and services
- Computational Peptide Drug Discovery Platform A next-generation peptide drug discovery engine that combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space, enabling the design of peptide therapeutics with high specificity and binding characteristics comparable to or better than monoclonal antibodies for previously undruggable targets.
Quantifiable outcome
- The company aims to move its most advanced program to clinical stages
- +1 more outcomes
Companies that use Perpetual Medicines
Customer profileSegments3 records
Ideal customer profiles1 record
Perpetual Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Perpetual Medicines partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- TandemAIcorePerpetual Medicines merged with TandemAI, a drug discovery company with an AI-powered platform combining computational methods with wet lab capabilities. TandemAI raised a $22M Series A extension to support growth in small molecule business and its merger with Perpetual Medicines, enhancing the combined drug discovery and development process.
Scale indicators2 records
Perpetual Medicines competitors and assessment
Company assessmentDirect peers
- Generate Biomedicines: AI-driven generative biology company designing novel protein therapeutics with machine learning. Closely comparable as a generative-AI protein/peptide design platform pursuing previously undruggable targets — same architectural philosophy as Perpetual's AI + synthetic chemistry stack.
- Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide therapeutics (Bicycles) for oncology and other diseases. Directly comparable as a peptide-engineered modality platform pursuing intracellular and difficult-to-drug targets with differentiated chemistry — overlapping modality and target-class focus with Perpetual.
- PeptiDream: Japan-based peptide discovery company using a proprietary Peptide Discovery Platform System (PDPS) to identify non-standard peptides against diverse targets. Closely comparable as a discovery-stage peptide platform with multiple pharma partnerships, similar business model to Perpetual's computational peptide engine.
Broad incumbents
- Amgen: Global biopharmaceutical company with a significant biologics and peptide-based portfolio (e.g., osteoporosis, oncology). Comparable as a large incumbent in biologic/peptide therapeutics, though Amgen's business is far broader than Perpetual's discovery-stage platform.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning. Overlaps with Perpetual on the philosophy of integrating computation and wet-lab experimentation, though Recursion operates at much larger scale and across multiple modalities.
- Eli Lilly: Global pharma with leading peptide/incretin franchise and deep peptide R&D heritage (Byetta/Bydureon originated in Lilly research). Comparable on peptide therapeutics and incretin biology, and a likely strategic partner/acquirer — Lilly is also Perpetual CEO Blanchard and CSO Ye's former employer.
- Zealand Pharma: Danish peptide therapeutics company with a track record of approved peptide drugs (e.g., in metabolic disease) and a pipeline spanning rare disease and metabolic indications. Comparable on peptide modality and focus areas including metabolic disease.
- Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company developing oral and injectable peptides across endocrine and oncology indications. Comparable to Perpetual on the peptide-therapeutics modality and metabolic/oncology focus areas.
- Schrödinger: Computational drug discovery platform combining physics-based simulation with ML, with both internal pipeline and software/collaboration revenue. Comparable to Perpetual on the physics + AI computational methodology, though Schrödinger's platform is broader (small molecules and biologics) and includes established software business.
Emerging players
- Insitro: Machine-learning driven drug discovery company combining data generation (including induced pluripotent stem cells) with predictive models. Overlaps with Perpetual on the AI/ML drug discovery thesis, though Insitro focuses on small molecules and is more platform-data driven than peptide-chemistry driven.
Market position
Strengths5 records
Weaknesses5 records
Key risks6 records
Key highlights6 records
Customer concentration
Perpetual Medicines social profiles
Digital presencePerpetual Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
Perpetual Medicines leadership team
Management profileNumber of profiles
Perpetual Medicines funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Perpetual Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Perpetual Medicines
What does Perpetual Medicines do?
Perpetual Medicines is a fully integrated computational peptide therapeutics company developing a next-generation peptide drug discovery engine. The platform combines leading-edge computational physics methods and next-generation AI technologies with advanced synthetic chemistry to access vast, unexplored peptide chemical space and design peptide therapeutics targeting previously undruggable proteins, with an internal pipeline focused on oncology, autoimmune, and metabolic diseases.
Is Perpetual Medicines a public or private company?
Perpetual Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was Perpetual Medicines founded?
Perpetual Medicines was founded in 2023. It employs 1 to 10 people.
Where is Perpetual Medicines based?
Perpetual Medicines is headquartered in Shanghai, China, in the Asia region.
Who are Perpetual Medicines's main competitors?
Direct peers on record are Generate Biomedicines, Bicycle Therapeutics and PeptiDream. Broad incumbents are Amgen, Recursion Pharmaceuticals, Eli Lilly, Zealand Pharma, Crinetics Pharmaceuticals and Schrödinger. Insitro is listed as an emerging player.
Does Perpetual Medicines have an API?
No public API is recorded for Perpetual Medicines.
What industry is Perpetual Medicines in?
Perpetual Medicines's product category is Computational Peptide Drug Discovery. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2836.